Cedar Knolls-based MYOS Corporation, an emerging biotherapeutics and bionutrition company, announced Thursday the appointment of Robert C. Ashton as chief medical officer.
According to the announcement, Ashton will lead the company's clinical research efforts and serve on the management committee and the joint research and development committee. He will also be responsible for the expansion of MYO-T12, known as Fortetropin, and sold under the brand name MYO-X. MYOS plans to conduct further clinical studies of the drug in the treatment of age-associated muscle loss and sarcopenia associated with chronic illnesses such as cancer.
Ashton has over 25 years of experience both as a surgeon and in building healthcare businesses. He is a board-certified thoracic and general surgeon and has broad clinical experience. He previously was the chief and vice-chairman of the Cancer Center at Hackensack University Medical Center, the announcement said.
ALSO ON NJBIZ: